Stories from MedEsthetics

Business Education for Medical Practitioners
Visit us at
Thursday, August 10, 2017 - 11:00
Bonti, a clinical-stage biotechnology company, has announced topline results of the first clinical study of its lead product candidate, EB-001, in glabellar lines. EB-001 is a novel serotype E botulinum neurotoxin with a unique efficacy profile, characterized by fast onset of action (about 24 hours) and short duration of effect (about 4 weeks).
Thursday, August 10, 2017 - 10:56
The American Society for Laser Medicine & Surgery (ASLMS) is hosting its 8th Annual Laser Aesthetics Course October 28-29, 2017, at the Beckman Laser Institute in Irvine, California.
Thursday, August 10, 2017 - 10:48
Practices can save money and downtime by considering future needs as they investigate IT options.By David J. WaldronTechnology plays an integral role in healthcare today. Not only have electronic medical records (EMR) become the law of the land, but practices also benefit from the use of practice management software and integrated sys­­tems that offer online booking, lead tracking and social media management. Implementing EMR and practice management systems involves a number of challenges in that they are costly, they evolve rapidly and they can quickly become obsolete. Therefore, it is...
Thursday, August 3, 2017 - 12:34
Valeant is rebranding its dermatology products under the name Ortho Dermatologics, which was acquired by Valeant in 2011. The rebranding coincides with the company’s launch of SILIQ, a biologic drug approved for the treatment of psoriasis. “The branding under Ortho Dermatologics allows us to showcase what we have as a company,” says William (Bill) Humphries, executive vice president of dermatology at Valeant. “We have more than 100 years of dermatology experience on the team now and we have a portfolio of dermatology products that, I think, is unrivaled in the industry.”
Thursday, August 3, 2017 - 12:31
In July, Ohio became the seventh state to pass SUNucate legislation, a nationwide effort led by the American Society for Dermatologic Surgery Association (ASDSA). The law eliminates barriers prohibiting students from possessing and using over-the-counter sunscreen by exempting these products from ”medication bans” in schools that require a physician’s note or prescription. In addition to Ohio, Alabama, Arizona, Florida, Louisiana, Utah and Washington state have also approved similar measures this year.
Thursday, August 3, 2017 - 12:28
Ideal Implant, founded in 2006 to develop, manufacture and market the saline IDEAL IMPLANT Structured Breast Implant has appointed Paul Herchman, co-founder and former CEO of ThermiGen, to its board of directors. He will act as a consultant in corporate development. Current board member Kevin Morano will assume the role of chief financial officer, continuing to lead the company's financial strategy, and Gabe Walters has been promoted from national sales director to vice president of U.S. sales.
Thursday, August 3, 2017 - 12:26
Two small-scale studies highlight the potential of silver particles to improve the efficacy of laser hair removal and light-based acne treatments.By Inga HansenAs aesthetic treatments become more varied and efficacious, there remain some key gaps in treatment options. For example, laser hair removal is one of the most pop­ular services offered in aesthetic practices and medspas, yet permanent hair reduction is not an option for those with blonde and red hair. Dermatologists have long sought an alternative to systemic treatments for those with moderate-to-severe acne, and while laser...
Thursday, July 27, 2017 - 12:55
Medical aesthetics company Sientra has acquired Miramar Labs for $20 million in upfront cash, plus contractual rights for potential contingent payments of up to $14 million in cash upon the achievement of certain milestones. The acquisition brings the miraDry system, the only FDA-cleared device to reduce underarm sweat, odor and permanently reduce hair of all colors, to Sientra’s product portfolio.
Thursday, July 27, 2017 - 12:51
Allergan has acquired the Regenica growth factor-based skincare line, and will market the line’s proprietary multipotent cell-conditioned media, which was developed by regenerative medicine company Histogen. Allergan plans to incorporate the technology, known as Multipotent Resignaling Complex (MRCx), in future products under the SkinMedica portfolio.
Thursday, July 27, 2017 - 12:48
Sebacia announced that it has completed a $20 million Series D financing to complete a U.S. pivotal trial of its proprietary microparticle treatment for moderate to severe acne.
Thursday, July 27, 2017 - 12:44
Physicians share their most popular and effective combination treatment regimens.By Inga HansenPatients seeking skin rejuvenation procedures typically present with a variety of concerns ranging from skin laxity to brown spots, visible vascularity, and fine lines and wrinkles. Delivering optimal outcomes often requires the use of multiple treatment modalities. This has led physicians to embrace combination treatments that enable them to treat several signs of aging in one treatment session, saving patients both time and money.
Thursday, July 20, 2017 - 12:04
Absorbable facial suspension sutures made of poly-l-actic acid (PLLA) and poly-lactide-co-glycolide (PGLA) offer benefits to patients with moderate facial aging who require more correction than can be achieved with injectable soft tissue fillers, according to an evidence review of suture lift technologies published in the Journal of Drugs in Dermatology (July 2017).
Thursday, July 20, 2017 - 12:02
Ariel E. Eber, MD, et al, from the University of Miami Miller School of Medicine, conducted a follow-up to a 2014 study that evaluated 472 sunscreens available at two major U.S. retailers (WalMart and Walgreens) to see if they met the American Academy of Dermatology’s recommendations. Dr. Eber and colleagues found that, in 2017, more sunscreens complied with the AAD’s recommendations than in 2014. The recommendations, which were released following the U.S. FDA’s 2011 standardization of sunscreen labeling, include:
Thursday, July 20, 2017 - 11:57
Valeant Pharmaceuticals has entered into an agreement to sell its Obagi Medical Products business for $190 million in cash to Haitong International Zhonghua Finance Acquisition Fund I. Valeant will use proceeds from the sale to permanently repay term loan debt under its Senior Secured Credit Facility. The transaction is expected to close in the second half of 2017, subject to customary closing conditions, including receipt of applicable regulatory approvals.
Thursday, July 20, 2017 - 11:31
Opinions vary on whether pre-treating the skin improves outcomes of ablative laser procedures, but the literature does offer some guidance.By Linda W. LewisThe value of pretreatment skincare protocols for ablative laser procedures has been debated for decades. In 1998, doctors at Massachusetts General Hospital Dermatology Laser Center published the results of a survey and literature review on the effect of pre- and postprocedure skincare protocols in laser skin resurfacing (Dermatologic Surgery, February). The two main reasons postulated for treating the skin before invasive procedures are...
Thursday, July 13, 2017 - 12:58
Wendy Roberts, MD, has developed a devoted following by helping her patients maintain and improve their skin health from head to toe.By Shelley Moench-Kelly, MBAWhen Wendy Roberts, MD, applied to Sarah Lawrence College in New York, a career in medicine was far from her mind. “I was going to major in dance,” she says. “I danced for the Dance Theatre of Harlem and the Garden State Ballet.”
Thursday, July 13, 2017 - 12:50
Allergan Chairman and CEO Brent Saunders authored a blog post from the CEO on the company’s website in which he shared his concern and discomfort with the growing number of minors undergoing cosmetic enhancement. In the post, he encouraged the medical aesthetics industry to start a dialogue on this topic in an effort to find consensus and provide guidelines for the treatment of minors. Following is Saunder’s post in full:
Thursday, July 13, 2017 - 12:48
Novan Pharmaceutical’s SB204, an investigational once-daily, topical nitric oxide-based monotherapy for the treatment of acne vulgaris, showed superior efficacy to placebo and a high level of safety in a phase 3 pivotal trial focused on adolescent use.


Advertisement - Box 1

Advertisement - Box 2

Advertisement - Box 3

Advertisement - Box 4

Advertisement - Box 5

Advertisement - Box 6